About the book
As the diagnostic and therapeutic modalities have been rapidly improved in the past several decades，most medical intervention techniques and/or drugs, especially for the anti-cancer treatment, might unavoidably result in various cardiotoxicities. Most anti-cancer treatments were found to be associated with various cardiovascular side effects impacting cancer patient’s outcomes, which has been a heavy concern both in the oncology and cardiology community. It has also been reported that cardiovascular causes are responsible for the death of 33% of cancer survivors. Most anti-cancer agents including cytotoxic drugs, molecular target agents and immune checkpoint inhibitors might induce acute or chronic cardiac toxicities and each of them has its own molecular mechanisms to the cardiac damage. Similarly, Radiation therapy, especially radiotherapy to the thoracic tumors, will unavoidably deliver an unnecessary radiation dose to the heart and result in some cardiac toxicities.
Though cardiovascular diseases in cancer patients can precede the diagnosis of cancer or can be related to the malignancy itself or its therapy, the oncologists and cardiologist should collaborate tightly to optimize the anti-cancer strategies and cardiovascular conditions before, during and after the cancer treatment course to best the patient’s outcome. Also, scientists should widely investigate mechanisms of cardiotoxicities to better manage side effects and promote advanced cardiovascular discoveries.
The recognition, prevention, monitoring (biomarkers or imaging), management of cancer treatment heart disease should be critical for the clinical practice and many cardiac sparing strategies have been developed and used in breast cancer, lung cancer, etc, which seem to minimize cancer treatment-related cardiac toxicities. In addition, some painkillers, and medical treatment also lead to a kind of cardiotoxicities, which would be introduced in this book.